The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Explore this paper's citation graph
Summary
In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.
- Type
- article
- Published
- 2016-08-31
- Cited by
- 2,732
- References
- 43
- OpenAlex
- https://openalex.org/W2510806376
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205250312
Keywords
Neurodegeneration, Monoclonal antibody, Neurotoxicity, Tolerability, Amyloid (mycology)
References
- Small Aβ1–42 oligomer‐induced membrane depolarization of neuronal and microglial cells: Role of N‐methyl‐D‐aspartate receptors
- The therapeutics of Alzheimer's disease: Where we stand and where we are heading
- Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
- Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
- Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.
- Molecular Mechanisms of Amyloid Oligomers Toxicity
- Current thinking on the mechanistic basis of Alzheimer's and implications for drug development
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods
- Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
- Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease.
- Robust amyloid clearance in a mouse model of AD provides novel insights into the mechanism of Aβ immunotherapy
- Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
- P2–411: Amelioration of calcium dyshomeostasis by immunotherapy with BIIB037 in Tg2576 mice
- Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease
- Metabotropic Glutamate Receptor 5 is a Co-Receptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
- Alzheimer's disease: the amyloid cascade hypothesis.
Cited by
- Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
- Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy
- THE PREVENTION OF ALZHEIMER’S DISEASE: LESSONS LEARNED AND APPLIED
- A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study
- Anticoagulants inhibit proteolytic clearance of plasma amyloid beta
- Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms
- Perioperative implications of common and newer psychotropic medications used in clinical practice.
- Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting
- Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline
- Update on Alzheimer's Disease Therapy and Prevention Strategies.
- Maladie d'Alzheimer : Impact extracellulaire et intracellulaire du peptide ß-amyloïde sur la transmission synaptique glutamatergique
- Alzheimer's disease: Attack on amyloid-β protein
- Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting.
- Alzheimer’s treatment appears to alleviate memory loss in small trial
- Alzheimer disease: Anti-Aβ antibody treatment shows promise in Alzheimer disease
- Dysregulation of neuronal calcium homeostasis in Alzheimer’s disease – a therapeutic opportunity?
- Towards Personalized Intervention for Alzheimer’s Disease
- Hybrid Antioxidant and Metal Sequestering Small Molecules Targeting the Molecular Features of Alzheimer’s Disease
- Microglia Function in the Central Nervous System During Health and Neurodegeneration
- Multiple Targets for the Management of Alzheimer's Disease.
Related papers
- Disease-associated protein seeding suggests a dissociation between misfolded protein accumulation and neurodegeneration in prion disease
- Nature of Tau-Associated Neurodegeneration and the Molecular Mechanisms
- A Possible Neurodegeneration Mechanism Triggered by Diabetes.
- Temperature-sensitive paralytic mutants are enriched for those causing neurodegeneration in Drosophila.
- The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Aβ peptides
- [Prevention of oxaliplatin-related neurotoxicity by glutathione infusions].
- The effects of meso-2,3-dimercaptosuccinic acid and oligomeric procyanidins on acute lead neurotoxicity in rat hippocampus.
- Spherulites in Human Brain Tissue are Composed of Beta Sheets of Amyloid and Resemble Senile Plaques